Tags

Type your tag names separated by a space and hit enter

Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
Nature. 2020 08; 584(7821):437-442.Nat

Abstract

During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-21-5. Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC50 values) as low as 2 ng ml-1. In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.

Authors+Show Affiliations

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. drobbiani@irb.usi.ch. Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. drobbiani@irb.usi.ch.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Hospital Program Direction, The Rockefeller University, New York, NY, USA.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Center for Clinical Translational Science, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.Chan Zuckerberg Biohub, San Francisco, CA, USA.Chan Zuckerberg Biohub, San Francisco, CA, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA. bjorkman@caltech.edu.Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu. Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. mcaskey@rockefeller.edu.Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu. Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32555388

Citation

Robbiani, Davide F., et al. "Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals." Nature, vol. 584, no. 7821, 2020, pp. 437-442.
Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437-442.
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hägglöf, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H. H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., ... Nussenzweig, M. C. (2020). Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 584(7821), 437-442. https://doi.org/10.1038/s41586-020-2456-9
Robbiani DF, et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals. Nature. 2020;584(7821):437-442. PubMed PMID: 32555388.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Convergent antibody responses to SARS-CoV-2 in convalescent individuals. AU - Robbiani,Davide F, AU - Gaebler,Christian, AU - Muecksch,Frauke, AU - Lorenzi,Julio C C, AU - Wang,Zijun, AU - Cho,Alice, AU - Agudelo,Marianna, AU - Barnes,Christopher O, AU - Gazumyan,Anna, AU - Finkin,Shlomo, AU - Hägglöf,Thomas, AU - Oliveira,Thiago Y, AU - Viant,Charlotte, AU - Hurley,Arlene, AU - Hoffmann,Hans-Heinrich, AU - Millard,Katrina G, AU - Kost,Rhonda G, AU - Cipolla,Melissa, AU - Gordon,Kristie, AU - Bianchini,Filippo, AU - Chen,Spencer T, AU - Ramos,Victor, AU - Patel,Roshni, AU - Dizon,Juan, AU - Shimeliovich,Irina, AU - Mendoza,Pilar, AU - Hartweger,Harald, AU - Nogueira,Lilian, AU - Pack,Maggi, AU - Horowitz,Jill, AU - Schmidt,Fabian, AU - Weisblum,Yiska, AU - Michailidis,Eleftherios, AU - Ashbrook,Alison W, AU - Waltari,Eric, AU - Pak,John E, AU - Huey-Tubman,Kathryn E, AU - Koranda,Nicholas, AU - Hoffman,Pauline R, AU - West,Anthony P,Jr AU - Rice,Charles M, AU - Hatziioannou,Theodora, AU - Bjorkman,Pamela J, AU - Bieniasz,Paul D, AU - Caskey,Marina, AU - Nussenzweig,Michel C, Y1 - 2020/06/18/ PY - 2020/05/03/received PY - 2020/06/12/accepted PY - 2020/12/18/pmc-release PY - 2020/6/20/pubmed PY - 2020/8/28/medline PY - 2020/6/20/entrez SP - 437 EP - 442 JF - Nature JO - Nature VL - 584 IS - 7821 N2 - During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-21-5. Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC50 values) as low as 2 ng ml-1. In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective. SN - 1476-4687 UR - https://www.unboundmedicine.com/medline/citation/32555388/Convergent_antibody_responses_to_SARS_CoV_2_in_convalescent_individuals_ L2 - https://doi.org/10.1038/s41586-020-2456-9 DB - PRIME DP - Unbound Medicine ER -